A European clinical trial published in The Lancet found that sulthiame, an anticonvulsant originally synthesized in the 1950s to treat childhood epilepsy, reduced breathing interruptions by up to 50% in patients with moderate to severe obstructive sleep apnea. The double-blind trial enrolled 240 participants across five countries, with those taking 200–300 mg doses one hour before bed showing 30–50% fewer apnea episodes compared to placebo.

All sulthiame doses outperformed placebo across key metrics including overnight blood oxygen levels and daytime sleepiness. Researchers identified 200 mg as the optimal dose, balancing strong efficacy with minimal side effects. The drug works by stabilizing breathing control and increasing respiratory drive, reducing the likelihood of upper airway collapse during sleep.

The findings could pave the way for the first pill-based treatment for obstructive sleep apnea, a condition affecting an estimated one billion people worldwide. Currently, the standard treatment is CPAP machines, which many patients find uncomfortable and abandon. Researchers described sulthiame as "a new individualized pharmacotherapy" that addresses underlying airway dysfunction rather than relying on weight loss alone.